| Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. | |
| | |
MedLine Citation:
|
PMID: 15077068 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The renin-angiotensin-aldosterone system (RAAS) plays an integral role in blood pressure regulation and has long been a target of pharmacologic approaches to controlling blood pressure. Traditionally, clinical interventions involving the RAAS have focused mainly on inhibiting the action of angiotensin II with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and limited attention has been devoted to direct inhibition of the action of aldosterone. Recent advances in understanding the role of aldosterone in cardiovascular injury have elevated the importance of direct inhibition of the action of this hormone in the long-term control of blood pressure and have led to the development of the selective aldosterone blocker eplerenone. This article reviews the role of the RAAS in the development of hypertension and discusses the rationale for the use of eplerenone with other medications affecting the RAAS to control blood pressure. |
| | |
Authors:
|
Henry R Black |
Related Documents
:
|
381138 - An apraisal of the role of aldosterone and the sympathetic nervous system in essential ... 2536448 - Understanding the mechanism of adrenocortical steroid hypertension. 10373218 - Maternal hypertension and progeny blood pressure: role of aldosterone and 11beta-hsd. 20921428 - Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibit... 7564208 - Measurement of blood pressure and heart rate by telemetry in conscious unrestrained mar... 17225178 - Dynamic measurement of patellofemoral kinematics and contact pressure after lateral ret... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American heart journal Volume: 147 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-04-12 Completed Date: 2004-08-09 Revised Date: 2006-02-27 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 564-72 Citation Subset: AIM; IM |
Affiliation:
|
Department of Preventive Medicine, Rush Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA. Henry_Black@rush.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
blood,
physiology* Aldosterone Antagonists / therapeutic use* Angiotensin II / antagonists & inhibitors Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Antihypertensive Agents / therapeutic use Blood Pressure / physiology Cardiovascular Diseases / etiology*, mortality Drug Therapy, Combination Humans Hypertension / drug therapy* Renin-Angiotensin System / drug effects, physiology* Spironolactone / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/eplerenone; 11128-99-7/Angiotensin II; 52-01-7/Spironolactone; 52-39-1/Aldosterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phage-display technology and its application to experimental oncological therapy
Next Document: Report of the National Heart, Lung and Blood Institute-National Institute of Allergy and Infectious ...